The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Open accessAbstract
Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
(2001) · Defense Technical Information Center (DTIC) · Cited by 2,158
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Shea, B. J., Hamel, C., Wells, G. A., Bouter, L. M., Kristjansson, E., Grimshaw, J., Henry, D. A., & Boers, M. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.10.009 · Cited by 1,755
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,292
Self-citationKlimstra, D. S., Modlin, I. R., Coppola, D., Lloyd, R. V., & Suster, S. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ec124e · Cited by 1,072
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Hallet, J., Law, C. H. L., Cukier, M., Saskin, R., Liu, N., & Singh, S. (2015) · Cancer · doi:10.1002/cncr.29099 · Cited by 852
Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00230-8 · Cited by 773
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W., Westwood, M. E., Mallett, S. V., Deeks, J. J., Reitsma, J. B., Leeflang, M., Sterne, J. A. C., & Bossuyt, P. M. (2011) · Data Archiving and Networked Services (DANS) · doi:10.1059/0003-4819-155-8-201110180-00009 · Cited by 601
External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR)
Shea, B. J., Bouter, L. M., Peterson, J., Boers, M., Andersson, N., Ortiz, Z., Ramsay, T., Bai, A., Shukla, V. K., & Grimshaw, J. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001350 · Cited by 569 · cited 1×
“Preventive Services Task Force criteria for randomized trials and cohort studies (33), Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) for diagnostic accuracy studies (34), and Assessment of Multiple Systematic Reviews (AMSTAR) for systematic reviews (35).”
MethodSomatostatin-Receptor Imaging in the Localization of Endocrine Tumors
Lamberts, S. W. J., Barker, W. H., Reubi, J.-C., & Krenning, E. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231805 · Cited by 532
Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J. (2008) · Cancer · doi:10.1002/cncr.23469 · Cited by 477
Mayo, S. C., de Jong, M. C., Pulitano, C., Clary, B. M., Reddy, S. K., Gamblin, T. C., Celinksi, S. A., Kooby, D. A., Staley, C. A., Stokes, J. B., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1154-5 · Cited by 475
Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.
Brix, G., Lechel, U., Glatting, G., Ziegler, S. I., Münzing, W., Müller, S. P., & Beyer, T. (2005) · PubMed · Cited by 458
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maecke, H. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 393
Sadowski, S. M., Neychev, V., Millo, C., Shih, J., Nilubol, N., Herscovitch, P., Pacak, K., Marx, S. J., & Kebebew, E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0987 · Cited by 353
Self-citationTang, L. H., Untch, B. R., Reidy, D. L., O'Reilly, E., Dhall, D., Jih, L., Basturk, O., Allen, P. J., & Klimstra, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0548 · Cited by 352
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Poeppel, T. D., Binse, I., Petersenn, S., Lahner, H., Schott, M., Antoch, G., Brandau, W., Bockisch, A., & Boy, C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.091165 · Cited by 346
Imaging of Neuroendocrine Tumors
Heller, M. T., & Shah, A. B. (2011) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2011.02.011 · Cited by 329
Chan, D. L., Pavlakis, N., Schembri, G. P., Bernard, E. J., Hsiao, E., Hayes, A., Barnes, T., Diakos, C., Khasraw, M., Samra, J., et al. (2017) · Theranostics · doi:10.7150/thno.18068 · Cited by 297
Academic Health Center Management of Chronic Diseases through Knowledge Networks: Project ECHO
Arora, S., Geppert, C. M. A., Kalishman, S., Dion, D., Pullara, F., Bjeletich, B., Simpson, G., Alverson, D. C., Moore, L. B., Kuhl, D., et al. (2007) · Academic Medicine · doi:10.1097/acm.0b013e31802d8f68 · Cited by 295
Deppen, S. A., Blume, J., Bobbey, A. J., Shah, C., Graham, M. M., Lee, P., Delbeke, D., & Walker, R. C. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165803 · Cited by 264
Self-citationDeppen, S. A., Liu, E., Blume, J. D., Clanton, J., Shi, C., Jones-Jackson, L. B., Lakhani, V., Baum, R. P., Berlin, J., Smith, G. T., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.163865 · Cited by 236
Self-citationLong-term survival after surgical management of neuroendocrine hepatic metastases
Glazer, E. S., Tseng, J. F., Al-Refaie, W., Solorzano, C. C., Liu, P., Willborn, K. A., Abdalla, E. K., Vauthey, J.-N., & Curley, S. A. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00198.x · Cited by 230
Frilling, A., Sotiropoulos, G. C., Radtke, A., Malago, M., Bockisch, A., Kuehl, H., Li, J., & Broelsch, C. E. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181fd37e8 · Cited by 222
Geijer, H., & Breimer, L. H. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2482-z · Cited by 212
SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
Kratochwil, C., Stefanova, M., Mavriopoulou, E., Holland-Letz, T., Dimitrakopoulou-Strauss, A., Afshar-Oromieh, A., Mier, W., Haberkorn, U., & Giesel, F. L. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0795-3 · Cited by 212
Barrio, M., Czernin, J., Fanti, S., Ambrosini, V., Binse, I., Du, L., Eiber, M., Herrmann, K., & Fendler, W. P. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185587 · Cited by 205
Self-citationBreeman, W. A. P., de Blois, E., Sze Chan, H., Konijnenberg, M., Kwekkeboom, D. J., & Krenning, E. P. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.001 · Cited by 203
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
Bombardieri, E., Ambrosini, V., Aktolun, C., Baum, R. P., Bishof-Delaloye, A., Del Vecchio, S., Maffioli, L., Mortelmans, L., Oyen, W., Pepe, G., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1473-6 · Cited by 193
SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours
Krausz, Y., Keidar, Z., Kogan, I., Even‐Sapir, E., Bar‐Shalom, R., Engel, A., Rubinstein, R., Sachs, J., Bocher, M., Agranovicz, S., et al. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01885.x · Cited by 192
Velikyan, I., Sundin, A., Sörensen, J., Lubberink, M., Sandström, M., Garske-Román, U., Lundqvist, H., Granberg, D., & Eriksson, B. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.126177 · Cited by 176
Yang, J., Kan, Y., Ge, B. H., Yuan, L., Li, C., & Zhao, W. (2014) · Acta Radiologica · doi:10.1177/0284185113496679 · Cited by 170
Measured Human Dosimetry of 68 Ga-DOTATATE
Walker, R. C., Smith, G. T., Liu, E., Moore, B., Clanton, J. A., & Stabin, M. G. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114165 · Cited by 148
Carcinoid and Neuroendocrine Tumors: Building on Success
Kunz, P. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2532 · Cited by 145
Self-citationRuf, J., Heuck, F., Schiefer, J., Denecke, T., Elgeti, F., Pascher, A., Pavel, M., Stelter, L., Kropf, S., Wiedenmann, B., et al. (2009) · Neuroendocrinology · doi:10.1159/000265561 · Cited by 125
Appropriate Use of Cardiovascular Technology
Hendel, R. C., Patel, M. R., Allen, J. M., Min, J. K., Shaw, L. J., Wolk, M. J., Douglas, P. S., Kramer, C. M., Stainback, R. F., Bailey, S. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.025 · Cited by 125
68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
Graham, M. M., Gu, X., Ginader, T., Breheny, P. J., & Sunderland, J. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191197 · Cited by 124
Self-citationEtchebehere, E., Santos, A. O., Gumz, B. P., Vicente, A., Hoff, P. G., Corradi, G., Ichiki, W. A., Filho, J. G. D. A., Cantoni, S., Camargo, E. E., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.144543 · Cited by 121
Krenning, E. P., Valkema, R., Kooij, P. P. M., Breeman, W. A. P., Bakker, W., DeHerder, W. W., Vaneijck, C. H. J., Kwekkeboom, D. J., DeJong, M. O., & Pauwels, S. (1999) · PubMed · Cited by 115
Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1
Sadowski, S. M., Millo, C., Cottle‐Delisle, C., Merkel, R., Yang, L., Herscovitch, P., Pacák, K., Simonds, W. F., Marx, S. J., & Kebebew, E. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.04.005 · Cited by 105
Self-citationBinnebeek, S. V., Vanbilloen, B., Baete, K., Terwinghe, C. Y., Koole, M. J. B., Mottaghy, F. M., Clément, P. M., Mortelmans, L., Bogaerts, K., Haustermans, K. M., et al. (2015) · European Radiology · doi:10.1007/s00330-015-3882-1 · Cited by 97
Changing paradigms with molecular imaging of neuroendocrine tumors.
Hofman, M. S., & Hicks, R. J. (2012) · PubMed · Cited by 86
Sawicki, L. M., Deuschl, C., Beiderwellen, K. J., Ruhlmann, V., Poeppel, T. D., Heusch, P., Lahner, H., Führer, D., Bockisch, A., Herrmann, K., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4803-2 · Cited by 82
Self-citationSomatostatin receptor imaging for neuroendocrine tumors
de Herder, W. W., Kwekkeboom, D. J., Feelders, R. A., van Aken, M. O., Lamberts, S. W. J., van der Lely, A. J., & Krenning, E. P. (2006) · Pituitary · doi:10.1007/s11102-006-0270-5 · Cited by 72
Versari, A., Camellini, L., Carlinfante, G., Frasoldati, A., Nicoli, F., Grassi, E., Gallo, C., Giunta, F. P., Fraternali, A., Salvo, D., et al. (2010) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181d6677c · Cited by 71
Ki-67 is a reliable pathological grading marker for neuroendocrine tumors
Nadler, A., Cukier, M., Rowsell, C. H., Kamali, S., Feinberg, Y., Singh, S., & Law, C. H. L. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1410-8 · Cited by 66
Froeling, V., Elgeti, F., Maurer, M. H., Scheurig‐Muenkler, C., Beck, A., Kröncke, T. J., Pape, U., Hamm, B., Brenner, W., & Schreiter, N. F. (2012) · Annals of Nuclear Medicine · doi:10.1007/s12149-012-0634-z · Cited by 63
Chapter 7: Grading a Body of Evidence on Diagnostic Tests
Singh, S., Chang, S., Matchar, D. B., & Bass, E. B. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2021-9 · Cited by 61
In Support of the ACR Appropriateness Criteria®
Sistrom, C. L. (2008) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2007.12.016 · Cited by 50
The ACR Appropriateness Criteria®: View From the Committee Chair
Bettmann, M. A. (2006) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2006.03.024 · Cited by 27
Appropriateness and Imaging Utilization
Thrall, J. H. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.02.019 · Cited by 26
Cited by
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Self-citationTsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Howe, J. R., Merchant, N. B., Conrad, C., Keutgen, X. M., Hallet, J., Drebin, J. A., Minter, R. M., Lairmore, T. C., Tseng, J. F., Zeh, H. J., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001454 · Cited by 396
Self-citationStrosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Self-citationTabarin, A., Assié, G., Barat, P., Bonnet, F., Bonneville, J. F., Borson-Chazot, F., Bouligand, J., Boulin, A., Brue, T., Caron, P., et al. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.02.001 · Cited by 59
Metadata
- Authors
- Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., May, L., Metz, D. C., Millo, C., O'Dorisio, S., Reidy-Lagunes, D. L., Soulen, M. C., & Strosberg, J. R.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-10-12
- Volume
- 59
- Issue
- 1
- Pages
- 66-74
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2761539086
- Cited by
- 363
- References
- 62
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.